{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:42:49Z","timestamp":1792658569600,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005690","name":"Universit\u00e4t des Saarlandes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>For the treatment of macular edema, in addition to the use of antivascular endothelial growth factors, steroids are also used intravitreally and sub-Tenon. Side effects include among others cataract formation and elevation of intraocular pressure (IOP). The aim of this retrospective study was to elicit the IOP elevation after administration of various steroidal medication, the time of onset, and the efficacy of the administered IOP-lowering therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 428 eyes with a postoperative (<jats:italic>n<\/jats:italic>\u2009=\u2009136), diabetic (<jats:italic>n<\/jats:italic>\u2009=\u2009148), uveitic macular edema (<jats:italic>n<\/jats:italic>\u2009=\u200961), and macular edema after retinal vein occlusion (<jats:italic>n<\/jats:italic>\u2009=\u200983). These patients were treated with one or more diverse steroidal agents once or multiple times. These drugs included: triamcinolone acetonide (TMC) as intravitreal injection (TMC IVI) or sub-Tenon (TMC ST), as well as dexamethasone (DXM) and fluocinolone acetonide (FA) intravitreally. An increase of IOP of\u2009\u2265\u200925\u00a0mmHg was designated as pathological. A steroid response in anamnesis, the time of onset of IOP rise from the first administration, and the therapy administered were documented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 428 eyes, 168 eyes (39.3%) had IOP elevation up to a mean of 29.7 (SD\u2009\u00b1\u20095.6) mmHg, which occurred at a median of 5.5\u00a0months. Steroids most frequently leading to rise of IOP included DXM (39.1% of all eyes receiving that drug), TMC IVI (47.6%), TMC ST combined with DXM (51.5%), DXM with FA (56.8%), and TMC IVI with DXM (57.4%). A Kaplan\u2013Meier analysis and the Log Rank test showed a significant difference (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). IOP rise was treated as follows: 119 conservatively (70.8%), and 21 surgically (12.5%, cyclophotocoagulation 8.3%, filtering surgery 1.8%, in 4 the steroidal drug implant was removed 2.4%), and 28 eyes received no therapy (16.7%). Sufficient IOP regulation was achieved in 82 eyes (68.9%) with topical therapy. In 37 eyes (31.1%) with persistently elevated intraocular pressure, topical therapy had to be continued over the follow-up of 20\u2009\u00b1\u20097\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IOP increases after any type of steroid application are not rare. Results of our study let us suspect that especially therapy with intravitreal dexamethasone, either as a monotherapy or in combination with another steroid, tends to increase IOP more than other steroids. Regular IOP checks are necessary after each steroid administration, with possible initiation of long-term conservative and\/or surgical therapy if necessary.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-023-06163-5","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T09:02:22Z","timestamp":1689066142000},"page":"3569-3579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases"],"prefix":"10.1007","volume":"261","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-0154","authenticated-orcid":false,"given":"Agata Anna","family":"Wykrota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Din","family":"Abdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"L\u00f6w","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"6163_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90:262\u2013267. https:\/\/doi.org\/10.1136\/bjo.2005.081224","journal-title":"Br J Ophthalmol"},{"key":"6163_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMra0804630","volume":"360","author":"YH Kwon","year":"2009","unstructured":"Kwon YH, Fingert JH, Kuehn MH, Alward WL (2009) Primary open-angle glaucoma. N Engl J Med 360:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMra0804630","journal-title":"N Engl J Med"},{"key":"6163_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/0301-4738.73695","volume":"59","author":"DR Anderson","year":"2011","unstructured":"Anderson DR (2011) Normal-tension glaucoma (Low-tension glaucoma). Indian J Ophthalmol 59:97\u2013101. https:\/\/doi.org\/10.4103\/0301-4738.73695","journal-title":"Indian J Ophthalmol"},{"key":"6163_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701\u2013713. https:\/\/doi.org\/10.1001\/archopht.120.6.701. (discussion 829-830)","journal-title":"Arch Ophthalmol"},{"key":"6163_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.preteyeres.2016.09.003","volume":"56","author":"ME Fini","year":"2017","unstructured":"Fini ME, Schwartz SG, Gao X, Jeong S, Patel N, Itakura T, Price MO, Price FW Jr, Varma R, Stamer WD (2017) Steroid-induced ocular hypertension\/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res 56:58\u201383. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.09.003","journal-title":"Prog Retin Eye Res"},{"key":"6163_CR6","first-page":"293","volume":"48","author":"JM McLean","year":"1950","unstructured":"McLean JM (1950) Use of ACTH and cortisone. Trans Am Ophthalmol Soc 48:293\u2013296","journal-title":"Trans Am Ophthalmol Soc"},{"key":"6163_CR7","first-page":"805","volume":"187","author":"J Francois","year":"1964","unstructured":"Francois J (1964) Cortisone and eye strain. Ann Ocul (Paris) 187:805\u2013816","journal-title":"Ann Ocul (Paris)"},{"key":"6163_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.12688\/f1000research.19198.1","volume":"8","author":"R Sacconi","year":"2019","unstructured":"Sacconi R, Giuffr\u00e8 C, Corbelli E, Borrelli E, Querques G, Bandello F (2019) Emerging therapies in the management of macular edema: a review. F1000Res 8:1413. https:\/\/doi.org\/10.12688\/f1000research.19198.1","journal-title":"F1000Res"},{"key":"6163_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00347-016-0304-y","volume":"113","author":"EM Hoffmann","year":"2016","unstructured":"Hoffmann EM, Lamparter J (2016) Differentiation of ocular hypertension. Ophthalmologe 113:715\u2013728. https:\/\/doi.org\/10.1007\/s00347-016-0304-y","journal-title":"Ophthalmologe"},{"key":"6163_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/01.icu.0000193079.55240.18","volume":"17","author":"R Jones 3rd","year":"2006","unstructured":"Jones R 3rd, Rhee DJ (2006) Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 17:163\u2013167. https:\/\/doi.org\/10.1097\/01.icu.0000193079.55240.18","journal-title":"Curr Opin Ophthalmol"},{"key":"6163_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00347-017-0588-6","volume":"115","author":"C Spira-Eppig","year":"2018","unstructured":"Spira-Eppig C, Eppig T, Bischof M, Schie\u00dfl G, Milioti G, K\u00e4smann-Kellner B, Carstensen H, Schick B, Seitz B (2018) Per aspera ad astra\u202f: implementation of electronic patient records in a university eye hospital\u202f: Experience with FIDUS in the Clinic for Ophthalmology at the Saarland University Center UKS. Ophthalmologe 115:868\u2013877. https:\/\/doi.org\/10.1007\/s00347-017-0588-6","journal-title":"Ophthalmologe"},{"key":"6163_CR12","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, Vi\u00e9 AL, Agard \u00c9, Bellocq D, Denis P, Kodjikian L (2017) Safety of intravitreal dexamethasone implant (Ozurdex): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension. Retina 37:1352\u20131359. https:\/\/doi.org\/10.1097\/IAE.0000000000001369","journal-title":"Retina"},{"key":"6163_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00347-019-0911-5","volume":"117","author":"AD Abdin","year":"2020","unstructured":"Abdin AD, Suffo S, Bischoff-Jung M, Daas L, Pattm\u00f6ller M, Seitz B (2020) Advantages of a designated IVI center for a German university eye hospital. Ophthalmologe 117:50\u201357. https:\/\/doi.org\/10.1007\/s00347-019-0911-5","journal-title":"Ophthalmologe"},{"key":"6163_CR14","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.3390\/jcm11195537","volume":"11","author":"W Aljundi","year":"2022","unstructured":"Aljundi W, Daas L, Abu Dail Y, K\u00e4smann-Kellner B, Seitz B, Abdin AD (2022) Topical NSAIDs and oral acetazolamide for macular edema after uncomplicated phacoemulsification: outcome and predictors of non-response. J Clin Med 11:5537. https:\/\/doi.org\/10.3390\/jcm11195537","journal-title":"J Clin Med"},{"key":"6163_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/01.iio.0000176353.56990.3b","volume":"45","author":"L Sobrin","year":"2005","unstructured":"Sobrin L, D\u2019Amico DJ (2005) Controversies in intravitreal triamcinolone acetonide use. Int Ophthalmol Clin 45:133\u2013141. https:\/\/doi.org\/10.1097\/01.iio.0000176353.56990.3b","journal-title":"Int Ophthalmol Clin"},{"key":"6163_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","volume":"110","author":"PM Beer","year":"2003","unstructured":"Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681\u2013686. https:\/\/doi.org\/10.1016\/S0161-6420(02)01969-3","journal-title":"Ophthalmology"},{"key":"6163_CR17","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.ophtha.2010.03.033","volume":"117","author":"L Shen","year":"2010","unstructured":"Shen L, You Y, Sun S, Chen Y, Qu J, Cheng L (2010) Intraocular and systemic pharmacokinetics of triamcinlone acetonide after a single 40-mg posterior subtenon application. Ophthalmology 117:2365\u20132371. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.033","journal-title":"Ophthalmology"},{"key":"6163_CR18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ajo.2006.05.023","volume":"142","author":"ER Thomas","year":"2006","unstructured":"Thomas ER, Wang J, Ege E, Madsen R, Hainsworth DP (2006) Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol 142:860\u2013861. https:\/\/doi.org\/10.1016\/j.ajo.2006.05.023","journal-title":"Am J Ophthalmol"},{"key":"6163_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ajo.2004.05.028","volume":"138","author":"M Inoue","year":"2004","unstructured":"Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y (2004) Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol 138:1046\u20131048. https:\/\/doi.org\/10.1016\/j.ajo.2004.05.028","journal-title":"Am J Ophthalmol"},{"key":"6163_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/IAE.0b013e318188c814","volume":"29","author":"JA Haller","year":"2009","unstructured":"Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM (2009) Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29:46\u201351. https:\/\/doi.org\/10.1097\/IAE.0b013e318188c814","journal-title":"Retina"},{"key":"6163_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00347-012-2737-2","volume":"111","author":"K Schmitz","year":"2014","unstructured":"Schmitz K, Maier M, Clemens CR, H\u00f6hn F, Wachtlin J, Lehmann F, Bertelmann T, R\u00fcdiger K, Horn M, Bezatis A, Spital G, Meyer CH, German Retinal Vein Occlusion Group (2014) Reliability and safety of intravitreal Ozurdex injections. The ZERO study. Ophthalmologe 111:44\u201352. https:\/\/doi.org\/10.1007\/s00347-012-2737-2","journal-title":"The ZERO study. Ophthalmologe"},{"key":"6163_CR22","unstructured":"ILUVIEN Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/27636. Accessed 22 Jan 2023"},{"key":"6163_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0300060518816884","volume":"47","author":"H Massa","year":"2019","unstructured":"Massa H, Nagar AM, Vergados A, Dadoukis P, Patra S, Panos GD (2019) Intravitreal fluocinolone acetonide implant (ILUVIEN\u00ae) for diabetic macular oedema: a literature review. J Int Med Res 47:31\u201343. https:\/\/doi.org\/10.1177\/0300060518816884","journal-title":"J Int Med Res"},{"key":"6163_CR24","unstructured":"Schmitt-Eilenberger VK, Augustin AJ (2013) Early experience with Iluvien for the treatment of chronic DME. Retina Today July\/August:34\u201337. http:\/\/retinatoday.com\/2013\/08\/early-experience-with-iluvien-for-the-treatment-of-chronic-dme\/"},{"key":"6163_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3109\/13816810.2016.1164193","volume":"38","author":"LP Doucette","year":"2017","unstructured":"Doucette LP, Walter MA (2017) Prostaglandins in the eye: Function, expression, and roles in glaucoma. Ophthalmic Genet 38:108\u2013116. https:\/\/doi.org\/10.3109\/13816810.2016.1164193","journal-title":"Ophthalmic Genet"},{"key":"6163_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/opo.12009","volume":"33","author":"RA Armstrong","year":"2013","unstructured":"Armstrong RA (2013) Statistical guidelines for the analysis of data obtained from one or both eyes. Ophthalmic Physiol Opt 33:7\u201314. https:\/\/doi.org\/10.1111\/opo.12009","journal-title":"Ophthalmic Physiol Opt"},{"key":"6163_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","volume":"127","author":"IU Scott","year":"2009","unstructured":"Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE StudyResearch Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127:1115\u20131128. https:\/\/doi.org\/10.1001\/archophthalmol.2009.233","journal-title":"Arch Ophthalmol"},{"key":"6163_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000317909","volume":"225","author":"Y Tao","year":"2011","unstructured":"Tao Y, Jonas JB (2011) Intravitreal Triamcinolone. Ophthalmologica 225:1\u201320. https:\/\/doi.org\/10.1159\/000317909","journal-title":"Ophthalmologica"},{"key":"6163_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","author":"MS Ip","year":"2009","unstructured":"Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH, SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study repost 5. Arch Ophthalmol 127:1101\u20131114. https:\/\/doi.org\/10.1001\/archophthalmol.2009.234","journal-title":"Arch Ophthalmol"},{"key":"6163_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ophtha.2004.10.042","volume":"112","author":"JB Jonas","year":"2005","unstructured":"Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA (2005) Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 112:593\u2013598. https:\/\/doi.org\/10.1016\/j.ophtha.2004.10.042","journal-title":"Ophthalmology"},{"key":"6163_CR31","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.ophtha.2005.03.023","volume":"112","author":"JA Cardillo","year":"2005","unstructured":"Cardillo JA, Melo LAS Jr, Costa RA, Skaf M, Belfort R Jr, Souza-Filho AAS, Farah ME, Kuppermann BD (2005) Comparison of intravitreal versus posterior sub-Tenon\u00b4s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 112:1557\u20131563. https:\/\/doi.org\/10.1016\/j.ophtha.2005.03.023","journal-title":"Ophthalmology"},{"key":"6163_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/02713680590934094","volume":"30","author":"P Mora","year":"2005","unstructured":"Mora P, Eperon S, Felt-Baeyens O, Gurny R, Sagodira S, Breton P, Guex-Crosier Y (2005) Trans-scleral diffusion of triamcinolone acetonide. Curr Eye Res 30:355\u2013361. https:\/\/doi.org\/10.1080\/02713680590934094","journal-title":"Curr Eye Res"},{"key":"6163_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000328630","volume":"47","author":"MR Razeghinejad","year":"2012","unstructured":"Razeghinejad MR, Katz LJ (2012) Steroid-induced iatrogenic glaucoma. Ophthalmic Res 47:66\u201380. https:\/\/doi.org\/10.1159\/000328630","journal-title":"Ophthalmic Res"},{"key":"6163_CR34","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1097\/IAE.0000000000003080","volume":"41","author":"A Rezkallah","year":"2021","unstructured":"Rezkallah A, Mathis T, Abukhashbah A, Voirin N, Malcl\u00e8s A, Agard \u00c9, Lereuil T, Denis P, Dot C, Kodjikian L (2021) Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections. The SAFODEX-2 study. Retina 41:1438\u20131445. https:\/\/doi.org\/10.1097\/IAE.0000000000003080","journal-title":"Retina"},{"key":"6163_CR35","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/eye.2016.301","volume":"31","author":"F Alfaqawi","year":"2017","unstructured":"Alfaqawi F, Lip PL, Elsherbiny S, Chavan R, Mitra A, Mushataq B (2017) Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye (Lond) 31:650\u2013656. https:\/\/doi.org\/10.1038\/eye.2016.301","journal-title":"Eye (Lond)"},{"key":"6163_CR36","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1038\/s41598-021-84362-y","volume":"11","author":"M Fallico","year":"2021","unstructured":"Fallico M, Maugeri A, Lotery A, Longo A, Bonfiglio V, Russo A, Avitabile T, Furino C, Cennamo G, Barchitta M, Agodi A, Marolo P, Ventre L, Caselgrandi P, Reibaldi M (2021) Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience. Sci Rep 11:4800. https:\/\/doi.org\/10.1038\/s41598-021-84362-y","journal-title":"Sci Rep"},{"key":"6163_CR37","unstructured":"Handzel DM, Briesen S, Romanou-Papadopoulou V, Dardenne CM, Remmel RM (2009) Behandlung des Irvine-Gass-Syndroms durch Sub-Tenon-Injektion von Triamcinolon. Retina and Uveitis 25\u201334"},{"key":"6163_CR38","unstructured":"Ozurdex Summary of Product Characteristics.\u00a0https:\/\/www.medicines.org.uk\/emc\/medicine\/23422. Accessed 22 Jan 2023"},{"key":"6163_CR39","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","volume":"36","author":"RK Maturi","year":"2016","unstructured":"Maturi RK, Pollack A, Uy HS, Varano M, Gomes AMV, Li XY, Cui H, Lou J, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group (2016) Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 36:1143\u20131152. https:\/\/doi.org\/10.1097\/IAE.0000000000001004","journal-title":"Retina"},{"key":"6163_CR40","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","volume":"118","author":"PA Pearson","year":"2011","unstructured":"Pearson PA, Comstock TL, Ip M, Callanan D, Morse LS, Ashton P, Levy B, Mann ES, Eliott D (2011) Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 118:1580\u20131587. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.048","journal-title":"Ophthalmology"},{"key":"6163_CR41","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/eye.2017.125","volume":"31","author":"C Bailey","year":"2017","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit Group (2017) Real-world experience with 0.2 \u00b5g\/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond) 31:1707\u20131715. https:\/\/doi.org\/10.1038\/eye.2017.125","journal-title":"Eye (Lond)"},{"key":"6163_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00417-017-3831-6","volume":"256","author":"X Li","year":"2018","unstructured":"Li X, Wang N, Liang X, Xu G, Li XY, Jiao J, Lou J, Hashad Y, China Ozurdex in RVO Study Group (2018) Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study. Graefes Arch Clin Exp Ophthalmol 256:59\u201369. https:\/\/doi.org\/10.1007\/s00417-017-3831-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6163_CR43","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","volume":"103","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Taylor SR, Koch FHJ, de Sousa JPC, Bailey C, ILUVIEN Registry Safety Study (IRISS) Investigators Group (2019) Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol 103:1072\u20131077. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312284","journal-title":"Br J Ophthalmol"},{"key":"6163_CR44","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/IAE.0000000000001364","volume":"37","author":"EK Chin","year":"2017","unstructured":"Chin EK, Almeida DRP, Velez G, Xu K, Peraire M, Corbella M, Elshatory YM, Kwon YH, Gehrs KM, Boldt HC, Sohn EH, Russell SR, Folk JC, Mahajan VB (2017) Ocular Hypertension after Intravitreal Dexamethasone (Ozurdex) Sustained-Release Implant. Retina 37:1345\u20131351. https:\/\/doi.org\/10.1097\/IAE.0000000000001364","journal-title":"Retina"},{"key":"6163_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/s0002-9394(01)01372-1","volume":"133","author":"DS Levin","year":"2002","unstructured":"Levin DS, Han DP, Dev S, Wirostko WJ, Mieler WF, Connor TB, George V, Eastwood D (2002) Subtenon\u00b4s depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Am J Ophthalmol 133:196\u2013202. https:\/\/doi.org\/10.1016\/s0002-9394(01)01372-1","journal-title":"Am J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06163-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T04:32:05Z","timestamp":1700800325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06163-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6163"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06163-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"19 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the Saarland University Medical Center and the Ethics Committee of the Medical Association of Saarland, Germany (Nr. 123\/20, date: 16.06.2020), as well as with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}